Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
198 studies found for:    "polycythemia vera"
Show Display Options
Rank Status Study
21 Terminated Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Erlotinib
22 Recruiting Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: Peg-P-IFN-alpha-2b (AOP2014);   Drug: Hydroxyurea
23 Terminated Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)
Condition: Polycythemia Vera
Interventions: Drug: Hydroxyurea;   Procedure: Phlebotomy
24 Completed Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Conditions: Polycythemia Vera;   Essential Thrombocytosis
Intervention: Drug: lestaurtinib
25 Active, not recruiting Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: PEG-P-INF alpha-2b (P1101)
26 Terminated Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Condition: Polycythemia Vera
Interventions: Drug: Clopidogrel (Plavix);   Drug: Placebo;   Drug: Aspirin
27 Active, not recruiting
Has Results
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Ruxolitinib
28 Active, not recruiting
Has Results
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Thrombocytosis
Intervention: Drug: Ruxolitinib
29 Active, not recruiting Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets;   Other: Best Available Therapy (BAT)
30 Completed Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
31 Recruiting Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis (PMF),;   Post-polycythemia Vera (Post-PV);   Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: Drug: Momelotinib;   Drug: Best Available Therapy (BAT)
32 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
33 Active, not recruiting Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Conditions: Idiopathic Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis;   Post Polycythemia-Vera Myelofibrosis
Interventions: Drug: panobinostat;   Drug: ruxolitinib
34 Recruiting A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Condition: Polycythemia Vera
Intervention: Drug: Givinostat
35 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
36 Active, not recruiting Pomalidomide for Myelofibrosis Patients
Conditions: Polycythemia Vera;   Thrombocythemia
Interventions: Drug: CC-4047;   Drug: Prednisone
37 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
38 Active, not recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
39 Recruiting Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy
40 Completed Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocytopenia
Intervention: Drug: Panobinostat

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years